Combining TT, such as PI3K inhibitors with CDK4/6 inhibitors, has shown promise in overcoming resistance, especially in ER-positive BC [181] (see Table 3, NCT05508906, NCT05768139). This evidence concerns the gene PIK3CD and breast cancer.